HK Stock Market Move | DUALITYBIO-B(09606) rose more than 13% in trading, recently announced plans to list on the Science and Technology Innovation Board. The company's total trading volume exceeded 6 billion US dollars.

DUALITY BIO-B (09606) rose more than 13% during trading hours, and as of the time of writing, it was up 11.1% at HK $314.4, with a turnover of HK $573 million. In terms of news, Ying'en Biotechnology previously announced that the company's board of directors had decided to list on the Sci-Tech Innovation Board, subject to market conditions, further approval from the board of directors, approval from the shareholders' meeting, and regulatory approval. It is reported that on April 15th of this year, Ying'en Biotechnology was officially listed on the main board of the Hong Kong Stock Exchange, raising a total of over HK $1.5 billion in its IPO, making it one of the largest IPOs in the HKEx 18A sector in the past four years. Sinolink released a research report stating that the rapid pace of innovation has stimulated large-scale transactions in the ADC technology field, with the company reaching multiple external licensing and cooperation agreements with leading companies in various industries globally, including BioNTech, BEIGENE, Adcendo, GSK, and Avenzo. The confirmed total BD revenue for the first half of 2023/2024/2025 is expected to be RMB 1.781 billion, RMB 19.37 billion, and RMB 12.27 billion respectively, with a total transaction value exceeding USD 6 billion.